EYE ON BIO

PERSPECTIVES ON BIOTECH INNOVATION *and* INVESTMENT IN LONDON *and* BEYOND

BIOTECH INVESTMENT:

Have the UK and Europe Come of Age?

Tuesday, June 9, 2015

The Wellcome Collection

Presented by

SIDLEY AUSTIN LLP SIDLEY

MedCity

KING'S College LONDON

EYE ON BIO

PERSPECTIVES ON BIOTECH INNOVATION AND INVESTMENT IN LONDON AND BEYOND

Tuesday, June 9, 2015 • The Wellcome Collection, London

AGENDA

2.00 P.M. **REGISTRATION**

2.30 P.M. **INTRODUCTION**

Roger Brownsword
Professor, King's College London

Mark Thompson
Partner, Sidley Austin LLP

2.45 P.M. ***PANEL ONE:***
REGULATORY STRATEGY AS A BUSINESS DRIVER

Roger Brownsword
Professor, King's College London

Dr. Peter Feldschreiber
Consultant, NDA Partners LLC

Dr. David Ebsworth
Chairman, Verona Pharma PLC

Dr. Alexander Natz
Secretary General, EUCOPE

Moderator: Vincenzo Salvatore
Senior Counsel, Sidley Austin LLP

3.45 P.M. ***PANEL TWO:***
WHAT ATTRACTS OR DETERS INVESTMENT?
LESSONS FROM INVESTORS IN EUROPE AND THE U.S.

Nooman Haque
Director of Life Sciences & Healthcare, Silicon Valley Bank

Jack Hollihan
Chairman, Litchfield Capital

Deborah Harland
Partner, SR One

Moderator: Mark Thompson
Partner, Sidley Austin LLP

4.45 P.M. **REFRESHMENT BREAK**

5.15 P.M. ***PANEL THREE:***
HOW CAN THE PUBLIC SECTOR ENCOURAGE INVESTMENT AND HOW CAN BIOTECH COMPANIES TAKE ADVANTAGE OF IT?

Steve Bates
CEO, BioIndustry Association

Zahid Latif
Head of Health&Care, Innovate UK

Moderator: Sarah Haywood
Chief Operating Officer, MedCity

6.15 P.M. **CLOSING REMARKS**

Mark Thompson
Partner, Sidley Austin LLP

6.30 P.M. **NETWORKING DRINKS**

SPEAKER BIOGRAPHIES

Steve Bates

CEO, BioIndustry Association

Steve Bates has been the Chief Executive of the BioIndustry Association (BIA) since 2012. Since then, the BIA has grown in membership by 25% and continues to influence and shape the sector on behalf of its members as well as providing a range of member benefits.

He has led the BIA campaigns for improved access to finance, championed the refilling of the Biomedical Catalyst and improvements to the R&D tax credits system, as well as showcasing the opportunity the sector presents to generalist long-term investors.

Steve also champions the adaptive pathway approach to the licensing of new drugs, and the need for Early Access to speed up the time it takes for innovative therapies to reach patients, and is particularly proud of the working relationship established with the UK leading medical research charities.

Steve attends the UK's Ministerial Industry Strategy Group, and was a member of the MHRA Expert Group on Innovation in Regulation and the UK Government's Regenerative Medicine Expert Group. Steve also sits on The Royal Society's Science, Industry & Translation Committee.

Beyond the UK, Steve sits on Europabio's National Association Council and is a founder member of the International Confederation of Biotech Associations.

Steve is an expert commentator on the sector with media including the *Financial Times, The Wall Street Journal* and *Bloomberg*, as well as BBC radio and television and Sky News, and is a regular presenter at industry-leading conferences.

Steve has worked both in biotech and the highest levels of UK government for over 15 years. He was Senior Director, External Affairs and Market Access at Genzyme UK and Ireland, during which time he worked on the establishment of the Office for Life Science and was a member of the BIA's Communications Advisory Committee.

Prior to joining the industry, Steve was special advisor to John Reid MP in his time in Tony Blair's Government working for the Home Secretary, the Secretary of State for Health, the Northern Ireland Secretary and the Defence Secretary to deliver policy initiatives as diverse as "Our inheritance, our future: realising the potential of genetics in the NHS 2003" to the implementation of the Serious Organised Crime Act of 2005.

Earlier in his career, Steve led the Labour Party media team into the general election of 2001 and was formerly a broadcast business journalist at Dow Jones and ITN. Steve is a Cambridge University graduate.

Roger Brownsword

Professor, King's College London

Roger Brownsword, who is a graduate of the London School of Economics, has been an academic lawyer for more than 40 years. Since he retired, he has held part-time professorial appointments at King's College London and Bournemouth University, he has been a visiting professor at Singapore Management University, and he is an honorary professor at the University of Sheffield. Currently, he chairs UK Biobank's Ethics and Governance Council and he is a member of the UK National Screening Committee; he was a member of the Nuffield Council on Bioethics (2004-2010), and he has acted as a specialist adviser to parliamentary committees on stem cells and hybrid embryos. His books include *Regulating Technologies* (with Karen Yeung), *Rights, Regulation and the Technological Revolution*, and *Law and the Technologies of the Twenty-First Century* (with Morag Goodwin). He is the founding general editor of *Law, Innovation and Technology* as well as being on the editorial board of journals that include the *Modern Law Review*, the *International Journal of Law and Information Technology*, and the *Journal of Law and the Biosciences*.

Dr. David Ebsworth

Ex CEO of Galenica/Headed Oxford Glycosciences/Ex global head of Bayer Pharma; Now Chairman Verona Pharma PLC

Dr David Ebsworth has more than 35 years' experience in the pharmaceutical, biotech and healthcare industries and has worked in Germany, Canada, the United States, and as a CEO in the UK and Switzerland. He has also served on boards in these countries as well as Austria, Holland, Italy, Romania, Israel and Japan. He has first-hand knowledge of the impact of regulatory, manufacturing and drug safety issues, as well as considerable knowledge of product marketing at all stages of the life cycle.

Peter Feldschreiber

Ex Senior Medical Assessor and Special Litigation Coordinator to the Commission on Human Medicines, MHRA; Now with NDA Partners LLC, and dually qualified as a barrister and physician

Peter Feldschreiber is dually qualified as a barrister and physician. He specialises in medical and healthcare law, including medical products liability, pharmaceutical and medical devices regulatory law, clinical negligence and personal injury and medically related employment litigation. Casework includes the Aspirin Reyes Syndrome product liability litigation, Nuclear Test Veterans Litigation, the morning after pill litigation, the Seroquel litigation, Fetal Anticonvulsants Litigation, Cochlear Implants and Cardiac Stent Litigations and judicial review and references to the ECJ on pharmaceutical regulatory issues. He has held appointments as Senior Medical Assessor and Special Litigation Coordinator to the Medicines and Healthcare products Regulatory Agency, Department of Health. He is co-author, together with Leigh-Ann Mulcahy, of the chapter on the regulation of healthcare products in Butterworths Healthcare Law and Practice. Dr Feldschreiber is General Editor of The Law and Regulation of Medicines (Oxford University Press) and is Consultant Editor for the Volume on Medical Products for Halsburys Laws of England and the Lexis Nexis series on updates of UK and European Law.

He is retained counsel to a number of solicitors and has experience of international litigation regarding drug induced injury. He has also published extensively on the Law of Causation and European Regulatory Procedure. He has published research into the repair of DNA following ionising radiation whilst working at the Institute of Cancer Research.

Nooman Haque

Director of Life Sciences & Healthcare, Silicon Valley Bank

Nooman Haque is the Director of Life Sciences with Silicon Valley Bank's UK Branch. He leads a team dedicated to supporting early, growth-stage and established businesses in all sectors of life sciences. Nooman is responsible for developing new relationships, identifying lending opportunities and working with the global life sciences team to support companies with all aspects of their business. He is actively involved within the sector, sitting on the BIA's Finance and Tax Committee, and is a frequent participant on panels and seminars.

Nooman joined Silicon Valley Bank from a venture capital firm in London and previously ran a sovereign wealth fund in Saudi Arabia largely focused on healthcare. His background includes strategic and financial advisory, debt and equity structuring and risk management.

Nooman has a BSC in psychology and MSC in economics, both from the University of London, and an MBA (finance) from Imperial College. He is a member of the British Psychological Society and the Royal Economic Society.

Deborah Harland

Partner, SR One

Deborah Harland joined SR One in 2005 to establish the firm's European investment office. She brings to SR One extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 20-year tenure in the pharmaceutical industry. Deborah is currently a member of the Board of Directors of Mission Therapeutics, Bicycle Therapeutics, Atopix Therapeutics, AtoxBio, f-star and VH Squared. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 2007), Pharmakodex Limited (sold to Orexo) and Syntaxin Limited (sold to Ipsen) and an observer on the Boards of Ablynx (IPO, Euronext Brussels, 2007) and 7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College.

Sarah Haywood

Chief Operating Officer, MedCity

Sarah Haywood became Chief Operating Officer of MedCity in October 2014, after fulfilling the role in an acting capacity since its launch in April 2014 alongside her position as Head of Life Sciences at London & Partners.

She is a graduate of the NHS Management Training Scheme in Wales and started her career in the NHS, working in a number of NHS Trusts, including Great Ormond Street NHS Foundation Trust, before joining Novartis Pharmaceuticals Research as the Head of Operations for a neuroscience drug discovery unit, located on the UCL campus.

From there, Sarah joined the civil service and undertook a number of roles as a member of the Senior Civil Service, including leading the DTI (now BIS) Bioscience Unit before it became part of the Office for Life Sciences. Her last role in BIS was leading the design and legislation for the extension of the right to request flexible working and the shared parental leave system. In January 2014 she joined London & Partners, where she worked with Dr Eliot Forster to establish MedCity.

Sarah has a degree in Biology from the University of Oxford, a post graduate diploma in management and an MA in human resources management; she is a chartered fellow of the Chartered Management Institute.

John "Jack" P. Hollihan III

Chairman, Litchfield Capital

Jack Hollihan is Executive Chairman of Litchfield Capital Holdings, Inc., a privately-held London- and U.S.-based investment management and advisory firm.

Jack has over 30 years' of global banking and investment/asset management experience, in London first at Morgan Stanley International, where he was responsible for several businesses and a member of the MSIIB Operating Committee, and then as Head of European Industry Investment Banking for Banc of America Securities (BAS), where he was a member of the BASL European Capital and Operating Committees and Board.

Jack is also the lead independent director of City Financial Investment Company Limited (London), a £2MM+ AUM global equity, fixed income and alternatives asset manager, and a trustee of ARMOUR Residential REIT, Inc. and JAVELIN Mortgage Investment Corp., with some $25Bn of assets under management. Additionally, Jack has acted as early stage director (and investor) for several tech/med tech startups, Recombine Inc. (bioinformatics) and Pixeus LLC (big data image recognition), which have been highly successful to date. Jack joined the board of each of these companies at their formation, and has helped guide their growth and positioning.

Jack received B.S. (Wharton) and B.A. degrees with honors from the University of Pennsylvania, and a J.D. from the University of Virginia School of Law. He is a dual UK/U.S. citizen.

Zahid Latif

Head of Health&Care, Innovate UK

Zahid Latif's first degree is in Pharmacy and after a year's pre-registration training at the Glasgow Royal Infirmary, he gained membership of the Royal Pharmaceutical Sciences. He went on to study for a PhD in natural product chemistry aimed at the discovery and identification of insecticidal compounds from tropical plants. The PhD was sponsored by ICI and Zahid spent time working at the Jeallott's Hill Research station in Bracknell.

After graduating Zahid worked for Xenova Discovery, firstly in Slough and later in Aberystwyth looking for novel plant secondary metabolites that could be used as tools for drug discovery. Following a management buy-out of the Aberystwyth labs, Zahid stayed on to work as Operations Manager for the newly formed MNLPharma and took responsibility for the delivery of their compound library generation.

After five years in Aberystwyth, Zahid moved on to work for Wyeth, as a clinical trials supplies pharmacist, to gain a broader perspective of the drug development process. Prior to joining Innovate UK (formerly the Technology Strategy Board), Zahid worked for Integrin in Oban, one of the first marine biotech companies in the UK, heading up operations for two years. As well as looking after the research portfolio, Zahid was responsible for delivering the company's algal toxin testing service which also included delivering a regulatory testing service for the Food Standards Agency in Scotland.

Zahid joined Innovate UK in October 2007 as Lead Technologist in Medicines and Healthcare and was promoted to Head of Healthcare in 2010.

Dr. Alexander Natz

Secretary General, EUCOPE

Since 2009, Alexander Natz has been Secretary General of the European Confederation of Pharmaceutical Entrepreneurs (www.eucope.org) in Brussels and works as a lawyer in his own law firm in Düsseldorf (www.natz-law.com). From 2008 to 2013, he was Head of the Brussels Office of *Bundesverband der Pharmazeutischen Industrie e.V. (BPI).* Previously, he was a lawyer with Sträter Law Firm in Germany, with a special focus on discount agreements and licensing of pharmaceuticals. Dr. Natz also was working in the field of competition law with the European Commission and the pharmaceutical industry. As research assistant at Duke University (USA), he has dealt with international pharmaceutical law. His doctorate was supervised by former judge at the European Court of Justice, Prof. Dr. Ulrich Everling.

Vincenzo Salvatore

Senior Counsel, Sidley Austin LLP

Vincenzo Salvatore is senior counsel in Sidley's Brussels office and a member of the firm's EU Life Sciences Regulatory team. His practice focuses on a broad array of regulatory and compliance matters. Vincenzo provides clients with strategic legal counseling on the EU's legal process regulating all aspects of the pharmaceutical industry, including enforcement issues, and data protection issues. He has extensive experience on all aspects of EU policies, with a particular focus on pharmaceutical regulation, as well as public procurement and public utilities.

He is an experienced litigator and has represented public authorities, companies and individuals before the European Court of Justice in Luxembourg in landmark EU law disputes.

Prior to joining the firm, Vincenzo served for eight years as Head of Legal Service at the European Medicines Agency (EMA), the agency responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. Vincenzo was responsible for defending the EMA's actions in court, coordinating legal advice and providing legal support and interpretative guidance to the EMA's governing bodies and its six Scientific Committees. He routinely represented the EMA before the European Court of Justice in Luxembourg, both in pharmaceutical and corporate-related legal proceedings, and was the EMA's Data Protection Officer.

Before serving with the EMA, Vincenzo was managing partner of a law firm with offices in Varese and Milan (Italy) where he assisted clients on implementation of EU law and in litigation before the European Court of Justice.

Vincenzo is a Full Professor of International Law at the University of Insubria – Varese (Italy) where he teaches EU law and international law. He speaks regularly at academic and professional conferences and routinely serves as a visiting lecturer at universities in Europe and the U.S., such as the British Institute of International and Comparative Law, Boston University School of Law, European Institute of Public Administration (EIPA) in Maastricht, University of Lisbon, *Europäischen Rechtsakademie* (ERA) in Trier, University of Southern California in Los Angeles and the University of Rome.

Vincenzo also writes extensively on EU and international topics and has published three books and more than 20 articles in distinguished law journals. He is an editorial board member of the *European Journal of Risk Regulation*.

Mark E. Thompson

Partner, Sidley Austin LLP

Mark Thompson has almost 20 years of experience advising clients on international M&A and private equity transactions and has practiced out of London for well over a decade.

Recognized as a leader in his field by *Chambers Global, Best Lawyers in the United Kingdom, Legal 500* and *London Super Lawyers*, Mark has extensive experience advising clients making investments in the U.S., Western and Eastern Europe, Russia and the Middle East. He regularly represents private equity funds with respect to their investment activity, as well as fund sponsors in the formation of those funds. Mark has significant experience advising companies and private equity funds on transactions in emerging markets, as well as on issues relating to the acquisition of distressed companies.

While Mark regularly represents clients in a variety of industries, including energy, telecommunications, banking and finance, transportation/logistics and retail, Mark has a particular focus on the life sciences/biotech, real estate and electronic payments industries. He combines his experience with Sidley's leading global life sciences regulatory practices to offer a full spectrum of advice surrounding transactions in the life sciences and biotech industries. The *LMG Life Sciences Guide* lists Mark as a "Life Sciences Star" for mergers and acquisitions and corporate and commercial work in the industry.

Mark regularly delivers presentations and has written on a variety of corporate law topics, frequently focusing on issues in connection with the life sciences industry, as well as international private equity and cross-border mergers and acquisitions and joint ventures.

NOTES

NOTES

PERSPECTIVES ON BIOTECH INNOVATION AND INVESTMENT
IN LONDON AND BEYOND

Tuesday, June 9, 2015 • The Wellcome Collection, London

Presented by Sidley Austin LLP, MedCity and King's College London

SIDLEY AUSTIN LLP
SIDLEY

MedCity

KING'S College LONDON